Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
Melanoma patients given Tecemotide alongside immunotherapy drug Keytruda were 49 per cent more likely to be alive three years later compared to those taking Keytruda alone.